Literature DB >> 15774812

Inhibition of angiogenesis: thalidomide or low-molecular-weight heparin?

Metin Ozkan, Bulent Eser, Ozlem Er, Gamze Gokoz Dogu, Mustafa Altinbas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15774812     DOI： 10.1200/JCO.2005.05.245

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Impact of tumour volume on the potential efficacy of therapeutic vaccines.

Authors:  J L Gulley; R A Madan; J Schlom
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

Review 2.  Targeting angiogenesis for the treatment of prostate cancer.

Authors:  Emmanuel S Antonarakis; Michael A Carducci
Journal:  Expert Opin Ther Targets       Date:  2012-03-13       Impact factor: 6.902

Review 3.  Angiogenesis inhibitors in the treatment of prostate cancer.

Authors:  Paul G Kluetz; William D Figg; William L Dahut
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

4.  Angiogenesis inhibition in prostate cancer: current uses and future promises.

Authors:  Jeanny B Aragon-Ching; Ravi A Madan; William L Dahut
Journal:  J Oncol       Date:  2010-02-11       Impact factor: 4.375

Review 5.  Angiogenesis inhibition in the treatment of prostate cancer.

Authors:  Ravi A Madan; William L Dahut
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

Review 6.  Thalidomide analogues as anticancer drugs.

Authors:  Jeanny B Aragon-Ching; Haiqing Li; Erin R Gardner; William D Figg
Journal:  Recent Pat Anticancer Drug Discov       Date:  2007-06       Impact factor: 4.169

7.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

Authors:  Philip M Arlen; James L Gulley; Catherine Parker; Lisa Skarupa; Mary Pazdur; Dennis Panicali; Patricia Beetham; Kwong Y Tsang; Douglas W Grosenbach; Jarett Feldman; Seth M Steinberg; Elizabeth Jones; Clara Chen; Jennifer Marte; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

8.  Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.

Authors:  Sharon L Sanborn; Matthew M Cooney; Afshin Dowlati; Joanna M Brell; Smitha Krishnamurthi; Joseph Gibbons; Joseph A Bokar; Charles Nock; Anne Ness; Scot C Remick
Journal:  Invest New Drugs       Date:  2008-05-10       Impact factor: 3.850
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.